Moreover, the combination of gemcitabine with ferroptosis inducers has demonstrated an enhancement of cytotoxic effects in SMAD4-positive organoids, proposing a viable combination therapy for pancreatic cancer [56]. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.